TRPV

TRPV Related Products (44):

By Type:	Pan (14) Selective (18)
By Effects:	Ligand (1) Inhibitors (6) Agonists (13) Antagonists (21) Activators (3)

Cat. No.	Product Name	Effect	Purity

HY-19608

GSK1016790A	Agonist	99.79%
GSK1016790A is a potent and selective transient receptor potential vanilloid 4 (TRPV4) channel agonist. GSK1016790A can elicit Ca²⁺ influx and elevate intracellular Ca²⁺ in HEK cells.

HY-10863

Anandamide	Activator	≥99.0%
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.

HY-12245

SB-366791	Antagonist	98.11%
SB-366791 is a potent and selective vanilloid receptor (VR1/TRPV1) antagonist (IC₅₀=5.7 nM). SB-366791 can be used for the research of inflammation.

HY-N0361

Dihydrocapsaicin	Agonist	99.93%
Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat.

HY-132222

SET2	Antagonist	99.78%
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases.

HY-P10762

CBP-1008	Ligand
CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma).

HY-W790266

Polygodial pyridazine	Agonist
Polygodial pyridazine (compound 7) is a polygodial analogue and a TRPV1 agonist with a GI₅₀ of 72 μM against MCF-7. Polygodial pyridazine can be utilized in cancer research.

HY-172774

TRPV1 antagonist 10	Antagonist
TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC₅₀ = 33.06 nM), moderate to weak URAT1 (IC₅₀ = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain.

HY-107436

LE135	Activator	≥99.0%
LE135 is a potent RAR antagonist that binds selectively to RARα (K_i of 1.4 μM) and RARβ (K_i of 220 nM), and has a higher affinity to RARβ. LE135 is highly selective over RARγ, RXRα, RXRβ and RXRγ. LE135 is also a potent TRPV1 and TRPA1 receptors activator with EC₅₀s of 2.5 μM and 20 μM, respectively.

HY-157131

TRPV2-selective blocker 1	Inhibitor	99.84%
TRPV2-selective blocker 1 (compound IV2-1) is a selective TRPV2 channel blocker with an IC₅₀ of 6.3 μM. TRPV2-selective blocker 1 does not affect TRPV1, TRPV3 or TRPV4 channels. TRPV2-selective blocker 1 also inhibits TRPV2-mediated Ca²⁺ influx in macrophages, and inhibits macrophage phagocytosis.

HY-P1651A

SOR-C13 TFA	Antagonist	99.18%
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.

HY-18662

RQ-00203078	Antagonist	99.84%
RQ-00203078 is a highly selective, potent and orally active TRPM8 antagonist with IC₅₀s of 5.3 nM and 8.3 nM for rat and human TRPM8 channels, respectively. RQ-00203078 shows little inhibitory action against TRPV1, TRPA1, TRPV4, or TRPM2 channels.

HY-131868

TRPV3 antagonist 74a	Antagonist	99.85%
TRPV3 antagonist 74a is a potent and selective TRPV3 antagonist. TRPV3 antagonist 74a displays no significant activity against a panel of other ion channels. TRPV3 antagonist 74a can be used for the research of neuropathic pain.

HY-100129

JNJ-17203212	Antagonist	99.94%
JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine.

HY-144372

TRPV1 antagonist 3	Antagonist	99.30%
TRPV1 antagonist 3 (Compound 7q) is a potent TRPV1 antagonist with an IC₅₀ of 2.66 nM against capsaicin. TRPV1 antagonist 3 is mode-selective, oral bioavailable (F = 60%) and CNS-penetrant.

HY-101323

Olvanil	Agonist	≥99.0%
Olvanil (NE-19550) is an analgesic and an agonist of transient receptor potential vanilloid type 1 (TRPV1) channels with an EC₅₀ of 0.7 nM.

HY-N8377

Capsiate	Agonist	99.85%
Capsiate, as a capsaicin analogue extracted from a non-pungent cultivar of CH-19 sweet red pepper, is an orally active agonist of TRPV1.

HY-P1651

SOR-C13	Antagonist	98.56%
SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity.

HY-P1651B

SOR-C13 acetate	Antagonist	98.56%
SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC₅₀ of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model.

HY-120294

Chrysin 6-C-glucoside 8-C-arabinoside	Inhibitor	99.11%
Chrysin 6-C-glucoside 8-C-arabinoside can inhibit the CGRP releasing and the activation of TRPV1 channel. Chrysin 6-C-glucoside 8-C-arabinoside can be used for anti-migraine research.

Name
Email *

	Sorry, but the email address you supplied was invalid.